Skip to content
‹ Back to IndustriesHealthcare

The Fungus from The Last of Us Could Help Fight Cancer

The Last of Us, HBO’s videogame-inspired zombie TV epic, opened to rave reviews last month. This drama, led by Game of Thrones stars Pedro Pascal and Bella Ramsey, shows a post-apocalyptic world that has been ravaged by the corydceps fungus after the fungus adapts for survival in the human body. Scarily enough, the fungus from…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The Last of Us, HBO’s videogame-inspired zombie TV epic, opened to rave reviews last month. This drama, led by Game of Thrones stars Pedro Pascal and Bella Ramsey, shows a post-apocalyptic world that has been ravaged by the corydceps fungus after the fungus adapts for survival in the human body. Scarily enough, the fungus from The Last of Us is very, very real, and it’s turned many more casual eyes to the world of mycology. Should people give the cordyceps fungus the horror treatment, though?

Cordyceps’ claim to fame isn’t off base; some species of the fungus are known to infect insects and basically, turn them into zombies. Interest in the series has raised questions of whether a cordyceps-fueled pandemic can actually threaten humanity. Experts in the field of mycology say it is highly improbable and would require major genetic changes, which would probably develop over the course of millions of years.

Although the fungus may be terrifying for invertebrates, outside of The Last of Us’s lore, cordyceps is actually quite useful for humans. It is a widely used ingredient in traditional Chinese medicine, and recent research shows it may even have anti-cancerous properties. So as media consumers clamor for cordyceps content, how is the science community approaching research around the zombie fungus? Leslie Samuel, founder of Interactive Biology, a Master’s in Neurobiology holder, and an experienced science educator, breaks down some of the most recent research surrounding the fungus from The Last of Us.

Leslie’s Thoughts:

“In the field of mycology, which is the study of fungi, there’s been a lot of interest in the cordyceps fungus. That’s the same type of fungus that the show, The Last of Us, is based on. We know that certain species of that fungus can infect ants, turning them into zombies, and when they get infected, those ants will climb up a tree and bite into it, basically committing suicide as the fungus takes over their bodies and [causes] them to release more spores so that they can infect more ants. And the cycle continues like in The Last of Us, but with ants.

But there are also studies that show that certain species of the cordyceps fungus have potential anti-cancer effects. They’ve demonstrated that certain extracts from some species of the cordyceps fungus seems to inhibit the growth of liver cancer. And other studies suggest that there are specific substances in some species that inhibit the inflammatory response in certain immune system cells in mice. Now, there’s still a lot more research that needs to be done to confirm that these effects can actually help in therapies in the future. But this entire field of mycology is fascinating, with these fungi having both harmful and potentially life-saving properties.”

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

New York City digital health startups raised $1.9 billion in Q3, up 36%

New York City digital health startups raised $1.9 billion in Q3, up 36%

New York City digital health startups raised $1.9 billion in Q3 2026, up 36% year over year. Nationally, Rock Health counted $3.7 billion raised by U.S. digital health startups across 114 deals in the quarter. Bigger checks and steady acquisitions mean buyers must assess which vendors are pulling ahead—and which may change owners mid-rollout.

  • 01New York's digital health startups grew Q3 funding 36% year over year, while U.S. digital health startups raised $3.7 billion across 114 deals in Q3, according to Rock Health.
  • 02Average U.S. digital health deal size has climbed from $20.6 million in 2024 to $31.0 million so far in 2026, so more of the money is going into bigger rounds.
  • 03Acquisition is still how most digital health companies exit, with 164 deals through Q3 2026 and no new public listings since August 2025. That makes a vendor's change-of-ownership terms a live contract question for buyers.

Nov 4, 2026

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS buys LookDeep Health and brings computer vision into hospital patient rooms

LeanTaaS said on November 3 it acquired LookDeep Health, a computer vision company, and introduced iQueue for Virtual Care, its first product built on what it calls ambient intelligence. Terms were not disclosed. The product bundles Virtual Observation, Virtual Nursing and Virtual Medicine, and LeanTaaS says hospitals can build on compatible cameras and in-room devices already installed or deploy supported hardware. The company cited reported results from LookDeep deployments, including fall-rate reductions of more than 70%, and said LookDeep's technology was evaluated in peer-reviewed research published in Frontiers in Imaging.

  • 01LeanTaaS acquired LookDeep Health and launched iQueue for Virtual Care, combining Virtual Observation, Virtual Nursing and Virtual Medicine; acquisition terms were not disclosed.
  • 02Hospitals can build on compatible cameras and in-room devices already in place or deploy supported hardware, according to LeanTaaS, which did not name camera vendors.
  • 03LeanTaaS reported results from LookDeep deployments including fall-rate reductions of more than 70% and twice as much nursing contact, figures that are the company's own and not tied to named health systems.

Nov 3, 2026

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Philips posts 8% order intake growth in Q3 and books a EUR 288 million Respironics provision

Royal Philips reported 8% comparable order intake growth for the third quarter of 2026, driven by Diagnosis & Treatment, with comparable sales up 3% to EUR 4.4 billion and an adjusted EBITA margin of 13.0%, up 70 basis points. The company reiterated its 2026 outlook for 3% to 4.5% comparable sales growth. Philips Respironics reached an agreement in principle with the US Department of Justice to resolve previously disclosed investigations related to its recall, and Philips recorded a EUR 288 million provision in the quarter, with payment expected in the first quarter of 2027 subject to final documentation.

  • 01Comparable order intake grew 8%, matching a year earlier, with Diagnosis & Treatment the driver; the equipment order book stands at about 40% of revenue.
  • 02Comparable sales rose 3% to EUR 4.4 billion, adjusted EBITA margin reached 13.0%, and free cash flow was EUR 384 million; the 2026 outlook was reiterated.
  • 03Philips Respironics reached an agreement in principle with the DOJ on previously disclosed recall investigations, and Philips recorded a EUR 288 million provision; the settlement is subject to final documentation.

Nov 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512